[The pharmacodynamics of theophylline (euphylline)].

A single intravenous administration of 2.4%-10.0 euphylline to 35 patients with obstructive affections of the lungs entailed a broncholytic effect in large airways in patients with reversible obstruction under sub-therapeutical theophylline concentrations in the serum.

[Comparison of two methods for therapeutic drug monitoring: FPIA (TDx) and Emit].

Two procedures of immunoassay used for therapeutic drug monitoring were studied: fluorescence-polarization immunoassay using specific reagents and analyzer TDx ("Abbott") and enzyme immunoassay using specific reagents from "Syva" and analyzer Centrifichem 600 ("Baker Instr"). Control blood sera containing known concentrations of theophylline and quinidine as well as blood sera from patients treated with these drugs were analyzed within low, middle and high ranges. The data of both these procedures correlated at the high rate (r-0.

[Clinical effectiveness of delayed-action theophylline preparations].

Clinical efficiency of course treatment has been assessed for 5 long-acting drugs of theophylline series: retaphylline (Finland), theo-dur (Sweden), durophylline (Yugoslavia), theopek and theobilong (USSR). The drugs were tested in 139 patients with chronic++ bronchial obstruction. It was established that first-line therapy with theophylline should be started with low doses (400 mg/day) and last for 3 days to define individual sensitivity to theophylline drugs followed by increasing doses.